| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7560445 | TARO | Process for preparing malathion for pharmaceutical use |
Feb, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7977324 | TARO | Process for preparing malathion for pharmaceutical use |
Aug, 2026
(2 years from now) | |
Ovide is owned by Taro.
Ovide contains Malathion.
Ovide has a total of 2 drug patents out of which 0 drug patents have expired.
Ovide was authorised for market use on 02 August, 1982.
Ovide is available in lotion;topical dosage forms.
Ovide can be used as treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.
The generics of Ovide are possible to be released after 01 February, 2027.
Drugs and Companies using MALATHION ingredient
Market Authorisation Date: 02 August, 1982
Treatment: Treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair
Dosage: LOTION;TOPICAL
How can I launch a generic of OVIDE before it's drug patent expiration?
More Information on Dosage
OVIDE family patents
